Trimebutine
- Generic Name
- Trimebutine
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29NO5
- CAS Number
- 39133-31-8
- Unique Ingredient Identifier
- QZ1OJ92E5R
- Background
Trimebutine is a spasmolytic agent that regulates intestinal and colonic motility and relieves abdominal pain with antimuscarinic and weak mu opioid agonist effects. It is marketed for the treatment of irritable bowel syndrome (IBS) and lower gastrointestinal tract motility disorders, with IBS being one of the most common multifactorial GI disorders . It is used to restore normal bowel function and is commonly present in pharmaceutical mixtures as trimebutine maleate salt form. Trimebutine is not a FDA-approved drug, but it is available in Canada and several other international countries.
- Indication
Indicated for symptomatic treatment of irritable bowel syndrome (IBS) and treatment of postoperative paralytic ileus following abdominal surgery.
- Associated Conditions
- Irritable Bowel Syndrome (IBS), Gastrointestinal spasms, Postoperative paralytic ileus
Exploring Treatments for Children's Abdominal Pain: Comparing Trimebutine and Probiotics
- Conditions
- Functional Abdominal Pain SyndromeFunctional Gastrointestinal DisordersIrritable Bowel Syndrome Variant of Childhood
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Universidad de Colima
- Target Recruit Count
- 82
- Registration Number
- NCT06268964
- Locations
- 🇲🇽
School of Medicine, University of Colima, Colima, Mexico
Trimebutine on the Development of Adverse Events Related to the Helicobacter Pylori Eradication Medications
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Chuncheon Sacred Heart Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT04403087
- Locations
- 🇰🇷
Chuncheon Sacred Heart hospital, Chuncheon, Gangwon, Korea, Republic of
Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients
- Conditions
- Irritable Bowel Syndrome
- Interventions
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Hospital Britanico
- Target Recruit Count
- 80
- Registration Number
- NCT03359499
- Locations
- 🇦🇷
Hospital Britanico, Buenos Aires, Caba, Argentina
Effect of Topical Trimebutine on Pain After Hemorrhoidectomy
- Conditions
- Hemorrhoids
- Interventions
- Procedure: Hemorrhoidectomy
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 42
- Registration Number
- NCT03036111
- Locations
- 🇪🇬
Mansoura university hospital, Mansoura, Dakahlia, Egypt
Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole
- Conditions
- Refractory Reflux Esophagitis
- Interventions
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Registration Number
- NCT02986685
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China
Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting
- Conditions
- NauseaVomiting
- Interventions
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- CM Chungmu Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT01984931
- Locations
- 🇰🇷
Chungmu General Hopsital, Seoul, Yeongdeungpo-gu, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.